Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Alexander M M EggermontChristian U BlankMario MandalaGeorgina V LongVictoria G AtkinsonStéphane DalleAndrew M HaydonAndrey MeshcheryakovAdnan KhattakMatteo S CarlinoShahneen SandhuJames M G LarkinSusana PuigPaolo Antonio AsciertoPiotr RutkowskiDirk SchadendorfRutger KoornstraLeonel Hernandez-AyaAnna Maria Di GiacomoAlfonsus J M van den EertweghJean-Jacques GrobRalf GutzmerRahima JamalPaul C LoriganAlexander C J van AkkooiClemens KreplerNageatte IbrahimSandrine MarreaudMichal KicinskiStefan SuciuCaroline RobertPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
In resected high-risk stage III melanoma, pembrolizumab adjuvant therapy provided a sustained and clinically meaningful improvement in RFS at 3-year median follow-up. This improvement was consistent across subgroups.